BREAST CANCER: Edited by Gottfried E. KonecnyUpdate on fertility preservation in young women undergoing breast cancer and ovarian cancer therapyLambertini, Matteoa,b; Ginsburg, Elizabeth S.c; Partridge, Ann H.aAuthor Information aDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA bDepartment of Medical Oncology, U.O. Oncologia Medica 2, IRCCS AOU San Martino-IST, Genova, Italy cCenter for Infertility and Reproductive Surgery, Brigham and Women's Hospital, Boston, Massachusetts, USA Correspondence to Ann H. Partridge, MD, MPH, Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, USA. Tel: +1 617 632 4587; fax: +1 617 632 2175; e-mail: [email protected] Current Opinion in Obstetrics and Gynecology: February 2015 - Volume 27 - Issue 1 - p 98-107 doi: 10.1097/GCO.0000000000000138 Buy Metrics Abstract Purpose of review The purpose of the article is to review the available options for fertility preservation in patients with breast and ovarian cancer, and the special issues faced by BRCA mutation carriers. Recent findings Future fertility is an important consideration for many young patients with cancer. There are both experimental and standard available strategies for patients with breast and ovarian cancer to preserve fertility, and each has potential advantages and disadvantages. Summary Embryo cryopreservation is widely available with a highly successful track record. Improvements in laboratory techniques have led to oocyte cryopreservation recently being recategorized as nonexperimental. Conservative gynecologic surgery is a standard consideration for patients with stage I ovarian cancer who desire future fertility. Ovarian tissue cryopreservation as well as ovarian suppression with luteinizing hormone-releasing hormone analogs during chemotherapy are considered experimental methods at this time, although recent data suggest both safety and efficacy for the use of luteinizing hormone-releasing hormone analogs in women receiving (neo)adjuvant chemotherapy for breast cancer. Special issues should be considered for women with BRCA mutations because of the need to undergo preventive surgery at young age. Multidisciplinary teams and well functioning relationships between the oncology and reproductive units are crucial to manage the fertility issues of young women with cancer. Copyright © 2015 YEAR Wolters Kluwer Health, Inc. All rights reserved.